Unilabs York Bioanalytical Solutions Adds Further Technology to Enhance Customer Satisfaction
Unilabs York Bioanalytical Solutions (YBS) has a history of employing cutting edge technology to maintain its place as Europe’s premier, independent bioanalytical facility. As part of this commitment to providing the latest technology to its clients, YBS is pleased to announce the acquisition of new systems that will help the company énhance its ability to provide high quality bioanalytical data to its clients with increased efficiency.
Two new Waters Xevo TQ-S LC-MS/MS systems will enable the detection and quantification of lower levels of conventional small molecule therapeutics, peptides and oligonucleotides. Linked to Waters Acquity UPLC systems or Spark Holland’s Symbiosis Pharma online, automated online solid phase extraction technology, these systems have proved invaluable in achieving ground breaking levels of sensitivity, selectivity and robustness.
Due to the high demand for sensitive peptide assays YBS has added an additional Spark Holland Symbiosis Pharma online, automated online system. The Symbiosis has been proven to be the technique of choice for peptide and oligonucleotide analysis. YBS will be presenting how this technology has revolutionised the analysis of biological therapeutics at several key scientific meetings this year.
To complement YBS’s other automated techniques, they are pleased to announce the purchase of a Hamilton Microlab Star Plus robotic system. This will enhance the analysis of biological samples and will be utilised for solid phase extraction and protein precipitation assays. The Hamilton Microlab Star Plus has a proven track record for precision, accuracy, reliability, flexibility and speed.
Since its launch in 1999, and becoming part of the Unilabs group in 2008, Unilabs York Bioanalytical Solutions has grown to become the largest, independent provider of bioanalytical services in Europe, offering pharmaceutical and Biotech companies an unprecedented standard of service. The company specialises in analysing drug concentrations (large and small molecules) in body fluids, biomarker analysis and sample logistics; an essential part of the drug development process.
For further information, please contact David Browne or Jeremy Cook at Unilabs York Bioanalytical Solutions on +441904 686060, or email your enquiry to info@yorkbio.com.
Further information about Unilabs York Bioanalytical Solutions can also be obtained from the company’s website www.yorkbio.com
Unilabs York Bioanalytical Solutions
Unilabs York Bioanalytical Solutions is a specialist provider of bioanalytical and biomarker analysis to pharmaceutical and biotech companies, supporting development of small and large molecule therapeutics, from discovery through to post-marketing.
YBS brings a fresh approach to contract bioanalytical research offering unsurpassed quality and delivery with scientific excellence. In addition YBS takes the pain out of sample logistics.
YBS is part of Unilabs, Europe’s leading diagnostic services company within laboratory and radiology service, with more than 3,600 employees in 12 countries. We make a difference to the development of new medicines